Clinical Trial Update: Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cisplatinum and everolimus in metastatic or unresectable extrapulmonary neuroendocrine carcinomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinomas

Drugs mentioned

• Everolimus (everolimus)
• cisplatinum

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Neuroendocrine Carcinomas | Phase 2 | Status: UNKNOWN